IPRICE: Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma
Study Details
Study Description
Brief Summary
This project aims to organise the sampling of blood and tumor at key points of the standard of care of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (HNSCC). This will allow to identify new potential predictive biomarkers of efficacy of immunotherapy and to investigate the evolution of the tumoral microenvironment after successive systemic treatments.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
Tumor and blood samples will be collected on patients treated by anti-PD1 immunotherapy at different timepoints. Tumor samples will be collected (i) before initiation of immunotherapy, (ii) at 50 days after initiation of immunotherapy and, optionally, in case of disease progression, (iii) before the initiation of the new line of chemotherapy and (iv) at 50 days after initiation of chemotherapy. Blood samples will be collected : (i) before initiation of immunotherapy, (ii) at each cycles of treatment until 84 days after initiation of immunotherapy and, optionally, in case of disease progression, (iii) before the initiation of the new line of chemotherapy and (iv) at each cycle until 50 days after initiation of chemotherapy (maximum 2 samples per month).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Recurrent and/or metastatic head and neck carcinoma Patients with indication of anti-PD1 immunotherapy according to recommendations |
Drug: Immunotherapy
anti-PD1
|
Outcome Measures
Primary Outcome Measures
- prospective validation of the expression of interferon-gamma signature to predict anti-PD1 immunotherapy response. [at 3 months after initiation of immunotherapy]
objective response according to RECIST v1.1 (response evaluation criteria in solid tumours)
- prospective validation of the expression of interferon-gamma signature to predict anti-PD1 immunotherapy response. [at 3 months after initiation of immunotherapy]
objective response according to iRECIST criteria (immune response evaluation criteria in solid tumours)
Secondary Outcome Measures
- Prospective validation of the expression of interferon-gamma signature to predict progression free survival. [at 3 years after inclusion]
Time from date of inclusion to the event of tumor recurrence or clinical progression or radiological progression on primary tumor or on lymph nodes or on metastasis or death whatever the cause.
- Prospective validation of the expression of interferon-gamma signature to predict overall survival. [at 3 years after inclusion]
Time from date of inclusion to death whatever the cause.
- Prospective validation of the expression of interferon-gamma signature to predict duration of objective response. [at 3 years after inclusion]
Time from date of first observation of objective response to progressive disease according to RECIST v1.1 or death..
- Exploratory outcome : investigation of the expression of other molecular signatures such as immune cells panel within the tumor microenvironment to predict anti-PD1 immunotherapy response. [at 3 months after initiation of immunotherapy]
objective response according to RECIST v1.1
- Exploratory outcome : investigation of the expression of other molecular signatures such as immune checkpoints protein expression level to predict anti-PD1 immunotherapy response. [at 3 months after initiation of immunotherapy]
objective response according to RECIST v1.1
- Exploratory outcome : investigation of the expression of other molecular signatures such as biomarkers expression level involved in immunogenic cell death and in mitophagy to predict anti-PD1 immunotherapy response. [at 3 months after initiation of immunotherapy]
objective response according to RECIST v1.1
- Exploratory outcome : investigation of the expression of other molecular signatures such as protein expression level involved in hypoxia to predict anti-PD1 immunotherapy response. [at 3 months after initiation of immunotherapy]
objective response according to RECIST v1.1
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with recurrent squamous-cell carcinoma of the head and neck not amenable to local therapy and/or with metastatic disease
-
Tumor directly accessible to clinical examination (tumor of oral cavity and of oropharynx) and/or cervical lymphadenopathy accessible to echography allowing to realise biopsy under local anesthesia
-
Indication to treatment by anti-PD1 immunotherapy according to French competent authority recommendations
-
Performance status 0, 1 or 2
-
At least one measurable lesion on RECIST V1.1 criteria
Exclusion Criteria:
-
Head and neck squamous cell carcinoma accessible to a local treatment
-
Cancer of nasopharynx, sinus or nasal cavity
-
Other histology than epidermoid
-
Patients with contraindication for anti-PD1 immunotherapy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Institut de cancérologie Strasbourg Europe | Strasbourg | France | 67033 |
Sponsors and Collaborators
- Institut de cancérologie Strasbourg Europe
- Centre National de la Recherche Scientifique, France
- Institut National de la Santé Et de la Recherche Médicale, France
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2021-003